| アブストラクト | BACKGROUND: Although children are known to be at risk of developing long COVID, its economic burden is poorly described. We aimed to assess the all-cause healthcare resource utilization (HCRU) and associated direct medical costs of children with mild-to-moderate long COVID in France. METHODS: This retrospective cohort study utilized The Health Improvement Network (THIN) primary care electronic health records to identify children aged <18 years with confirmed/probable COVID-19 diagnoses during March 2020 to December 2022 who developed long COVID, identified per the World Health Organization as suggestive symptoms present >/=3 months following SARS-CoV-2 infection. Patient characteristics, all-cause HCRU and direct healthcare costs from a national health insurance perspective were summarized. HCRU and costs were stratified into healthcare encounters, medical procedures, retail pharmacy usage, testing, caregiver sick leave, medical transport, and medical device usage. RESULTS: Of 27,537 children diagnosed with acute COVID-19, 3,888 (14.1%) developed long COVID; mean age was 8.9 years, 49.2% were female and, among those with comorbidity, 24.5% had a Charlson Comorbidity Index score >/=1. During a mean post-diagnosis follow-up of 12.6 months, 93.6% of children had general practitioner consultations, 93.5% had pharmacy usage, and 61.0% had medical procedures. First-year costs were highest at euro823 per patient per year; 4.3% of children required caregiver-related work absenteeism. Compared to children who did not develop long COVID, a long COVID diagnosis was associated with an incremental cost increase of euro98 per patient per year. LIMITATIONS: Our findings only represent a national payer perspective. The true societal burden of long COVID in children is likely underestimated since long COVID-related indirect costs are not fully captured and access to care varies. CONCLUSION: Children living with long COVID managed in the community pose a non-neglectable burden on French health insurance, reinforcing the importance of managing long COVID with a multidisciplinary approach and optimizing resource allocation. |
|---|
| ジャーナル名 | Journal of medical economics |
|---|
| Pubmed追加日 | 2025/6/27 |
|---|
| 投稿者 | Yang, Jingyan; Tamberou, Cheikh; Arnee, Elise; Squara, Pierre-Alexandre; Boukhlal, Ayoub; Nguyen, Jennifer L; Volkman, Hannah R; Fievez, Stephane; Lepoutre-Bourguet, Marina; Ben Romdhane, Haifa; Renaudat, Charlotte; Crepey, Pascal; Robineau, Olivier |
|---|
| 組織名 | Global Access and Value, Pfizer Inc, New York, NY, USA.;Institute for Social and Economic Research and Policy, Columbia University, New;York, NY, USA.;Real-world Evidence, GERS DATA, Paris, France.;Medical Affairs, Pfizer Ltd, Paris, France.;Health & Value, Pfizer Ltd, Paris, France.;EHESP, CNRS, Inserm, University of Rennes, Rennes, France.;Inserm, Institut Pierre Louis d'Epidemiologie et de Sante Publique, Sorbonne;Universite, Paris, France.;Centre Hospitalier Gustave Dron, EA2694, Centre Hospitalier de Tourcoing,;University Lille, Tourcoing, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40574623/ |
|---|
